Combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer live longer and control their disease better than with the standard treatment drug regorafenib, according to a study led by UCLA investigators.
NIH has introduced Linked Discoveries, an experimental tool designed to help scientists more easily see how an individual research finding relates to the larger body of biomedical evidence.
